TEK and breast carcinoma: Directly activating Tie2 with the Ang2-binding and TIE2-activating antibody (ABTAA) complex induces tumor normalization with increased pericyte and collagen type IV basement membrane coverage, which suppresses tumor cell metastasis and extravasation in glioma, Lewis lung carcinoma (LLC) and breast cancer [98].